Dr. Gregory J. Carven has served as Chief Scientific Officer (CSO) since February 2021 and joined Scholar Rock in 2014 as VP of Antibody Discovery and Protein Sciences and was promoted to Head of Research in June 2020. He is a recognized leader, with more than 15 years of experience in the discovery and development of antibody therapeutics. Gregory was recognized for the invention of Keytruda® (pembrolizumab) with his receipt of an award for “Inventor of the Year” in 2016 by the Intellectual Property Owners Education Foundation. Prior to joining Scholar Rock, Gregory led hybridoma based antibody discovery efforts at Pfizer and held positions of increasing responsibility at Merck Research Laboratories (formerly Schering Plough Research Institute and Organon Biosciences), and was a scientist at Phylogix, Inc. Gregory received his Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology, continued his research at the University of Massachusetts Medical School and received his B.S. from the University of Massachusetts Amherst.
Gregory J. Carven, PhD
Chief Scientific Officer